Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Pandion Therapeutics, Inc is a biotechnology business based in the US. Pandion Therapeutics shares (PAND) are listed on the NASDAQ and all prices are listed in US Dollars.
|Latest market close||USD$16.11|
|52-week range||USD$10.28 - USD$27.752|
|50-day moving average||USD$16.6314|
|200-day moving average||USD$15.5716|
|Wall St. target price||USD$25.67|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||N/A|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-07)||-9.60%|
|1 month (2020-12-16)||4.61%|
|3 months (2020-10-15)||42.44%|
|6 months (2020-07-13)||N/A|
|1 year (2020-01-13)||N/A|
|2 years (2019-01-13)||N/A|
|3 years (2018-01-13)||N/A|
|5 years (2016-01-13)||N/A|
|Revenue TTM||USD$7.6 million|
|Gross profit TTM||USD$967,000|
|Return on assets TTM||0%|
|Return on equity TTM||0%|
|Market capitalisation||USD$539.9 million|
TTM: trailing 12 months
There are currently 169,410 Pandion Therapeutics shares held short by investors – that's known as Pandion Therapeutics's "short interest". This figure is 67% down from 514,108 last month.
There are a few different ways that this level of interest in shorting Pandion Therapeutics shares can be evaluated.
Pandion Therapeutics's "short interest ratio" (SIR) is the quantity of Pandion Therapeutics shares currently shorted divided by the average quantity of Pandion Therapeutics shares traded daily (recently around 38155.405405405). Pandion Therapeutics's SIR currently stands at 4.44. In other words for every 100,000 Pandion Therapeutics shares traded daily on the market, roughly 4440 shares are currently held short.
However Pandion Therapeutics's short interest can also be evaluated against the total number of Pandion Therapeutics shares, or, against the total number of tradable Pandion Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Pandion Therapeutics's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Pandion Therapeutics shares in existence, roughly 10 shares are currently held short) or 0.0324% of the tradable shares (for every 100,000 tradable Pandion Therapeutics shares, roughly 32 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Pandion Therapeutics.
Find out more about how you can short Pandion Therapeutics stock.
We're not expecting Pandion Therapeutics to pay a dividend over the next 12 months.
Pandion Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing various therapeutics to address the unmet needs of patients suffering from autoimmune diseases. Its lead product candidate is PT101, an effector module comprised of an engineered variant of wild-type interleukin-2 (IL-2) fused to a protein backbone that is in Phase 1a clinical trials for the treatment of various autoimmune and inflammatory diseases. The company's other product candidates comprise PT627, a systemic PD-1 agonist that is in preclinical studies for the treatment of autoimmune diseases; PT001, a bifunctional molecule combining its PD-1 agonist effector with a tether module that binds to mucosal vascular addressing cell adhesion molecule (MAdCAM) to drive tissue-selective immunomodulation in the gastrointestinal tract; and PT002, a bifunctional molecule combining its IL-2 mutein effector with a tether module that binds to MAdCAM to drive tissue-selective immunomodulation in the gastrointestinal tract. It has a collaboration with Astellas Pharma Inc. to develop locally acting immunomodulators for autoimmune diseases of the pancreas. The company is headquartered in Watertown, Massachusetts.
Everything we know about the CDT Environmental Technology Investment Holdings Limited IPO, plus information on how to buy in.
Everything we know about the Viant Technology Inc IPO, plus information on how to buy in.
Steps to owning and managing EVGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ETL, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQBK, with 24-hour and historical pricing before you buy.
Steps to owning and managing EIGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ELTK, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNKN, with 24-hour and historical pricing before you buy.
Steps to owning and managing DKL, with 24-hour and historical pricing before you buy.
Steps to owning and managing DMAC, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.